指南与共识肝病

共识指南:慢性胆汁淤积性肝病成人临床试验中疑似急性药物性肝损伤的检测、评估和管理最佳实践

Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.
指南 / 共识 · Aliment Pharmacol Ther · 2019-11-25

该共识由IQ DILI倡议(16家药企与学术及监管专家合作)制定,针对原发性胆汁性胆管炎(PBC)和原发性硬化性胆管炎(PSC)成人患者,基于广泛文献回顾和专家讨论,提出临床试验中疑似急性药物性肝损伤(DILI)的肝脏入选标准、肝试验监测、疑似DILI信号处理及肝脏停药规则的最佳实践推荐。

要点

  • 推荐涵盖肝脏入选标准、肝试验监测、疑似DILI信号处理及肝脏停药规则。
  • 适用于PBC和PSC成人临床试验中疑似急性DILI的检测、评估和管理。
  • 由16家药企与学术及监管DILI专家合作制定,基于文献回顾与共识讨论。

核心结论

  • 为慢性胆汁淤积性肝病成人临床试验中疑似急性DILI的检测、评估和管理提供了框架。

研究设计与样本

  • 由IQ DILI倡议(16家药企成员与学术及监管DILI专家合作)制定,基于广泛文献回顾和深入讨论达成共识推荐。

主要发现

  • 推荐了关于肝脏入选标准、肝试验监测、疑似DILI信号处理及肝脏停药规则的最佳实践。

关键数值与推荐

  • 推荐条款涉及肝脏入选标准、肝试验监测、疑似DILI信号处理及肝脏停药规则。

临床怎么用

  • 可用于指导PBC和PSC成人临床试验中疑似急性DILI的检测、评估和管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Improved knowledge of the molecular pathophysiology and immunopathogenesis of cholestatic liver diseases in recent years has led to an increased interest in developing novel therapies. Patients with cholestatic liver disease often require different approaches to assessment and management of suspected drug-induced liver injury (DILI) compared to those with healthy livers and those with parenchymal liver diseases. At present, there are no regulatory guidelines or society position papers, that systematically address best practices pertaining to detection of DILI in these patients. AIMS: To outline best practices for detection, assessment and management of suspected acute DILI during clinical trials in adults with the cholestatic liver diseases - Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC). METHODS: This is one of the several papers developed by the IQ DILI Initiative, which is comprised of members from 16 pharmaceutical companies, in collaboration with DILI experts from academia and regulatory agencies. The contents are the result of an extensive literature review, as well as in-depth discussions among industry, regulatory and academic DILI experts, to achieve consensus recommendations on DILI-related issues occurring during clinical trials for cholestatic liver diseases. RESULTS: Recommended best practices are outlined pertaining to hepatic eligibility criteria, monitoring of liver tests, approach to a suspected DILI signal, and hepatic discontinuation rules. CONCLUSIONS: This paper provides a framework for the approach to detection, assessment and management of suspected acute DILI occurring during clinical trials in adults with cholestatic liver disease.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Palmer M, Regev A, Lindor K, et al. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Aliment Pharmacol Ther. 2019. PMID: 31762074. doi:10.1111/apt.15579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。